ORIGANUM MAJORANA ATTENUATES CIPROFLOXACIN-INDUCED NEPHROPATHY IN RATS

Wiad Lek. 2022;75(12):3046-3049. doi: 10.36740/WLek202212126.

Abstract

Objective: The aim: The researchers wanted to discover if Origanum majorana (O. M.) has any renoprotective qualities in a CIN rat model.

Patients and methods: Materials and methods: Control, ciprofloxacin (ciprofloxacin-induced CIN), two O. majorana groups (rats treated with O. majorana 30 mg and 45 mg), and two ciprofloxacin Plus O. majorana groups (n = 8) were randomly assigned to rats (CIN rats treated with O. majorana at 30 mg and 45 mg). Renal function tests were performed, as well as histological investigation.

Results: Results: The levels of serum blood urea nitrogen (BUN) and creatinine increased after ciprofloxacin treatment. The serum BUN and creatinine levels in the ciprofloxacin + O. majorana groups were lower as well as in O. majorana groups, however, kidney damage was higher in the ciprofloxacin group and reduced tissue damage in combination groups and O. majorana groups rats.

Conclusion: Conclusions: O. majorana decreases experimental CIN in vivo. This effect is thought to activate the antioxidant defenses pathway.

Keywords: ciprofloxacin; Origanum majorana; and anti-oxidants; creatinine; urea.

MeSH terms

  • Antioxidants / pharmacology
  • Creatinine / adverse effects
  • Kidney Diseases* / chemically induced
  • Kidney Diseases* / drug therapy
  • Oils, Volatile* / adverse effects
  • Origanum*

Substances

  • Creatinine
  • Oils, Volatile
  • Antioxidants